Oramed Pharmaceuticals Inc.
ORMP
$4.48
$0.102.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -- | -- | -- |
| Cost of Revenue | -100.00% | -100.00% | -- | -- | -- |
| Gross Profit | -100.00% | -100.00% | -- | -- | -- |
| SG&A Expenses | 45.17% | 21.44% | 35.05% | 11.44% | -10.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.33% | -12.70% | 33.70% | 14.91% | 21.81% |
| Operating Income | -6.22% | 0.50% | -18.05% | 0.40% | -6.26% |
| Income Before Tax | 1,091.52% | 637.79% | 573.14% | 678.66% | -199.25% |
| Income Tax Expenses | 2,162.63% | 480.14% | 255.26% | 331.37% | 22.83% |
| Earnings from Continuing Operations | 821.89% | 488.87% | 435.11% | 897.45% | -216.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -90.16% | -17.07% | -20.93% | -39.73% | -45.54% |
| Net Income | 823.74% | 489.55% | 436.04% | 882.13% | -215.82% |
| EBIT | -6.22% | 0.50% | -18.05% | 0.40% | -6.26% |
| EBITDA | -6.44% | 0.18% | -18.90% | -0.32% | -6.96% |
| EPS Basic | 808.43% | 482.76% | 424.66% | 831.10% | -216.59% |
| Normalized Basic EPS | 49.11% | 58.66% | -52.22% | 4.28% | 12.05% |
| EPS Diluted | 761.65% | 462.46% | 405.49% | 866.41% | -223.41% |
| Normalized Diluted EPS | 48.61% | 57.79% | -52.64% | 3.48% | 11.08% |
| Average Basic Shares Outstanding | -0.09% | 0.82% | 1.34% | 1.39% | 1.14% |
| Average Diluted Shares Outstanding | 1.61% | 2.30% | 1.64% | 1.08% | 0.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |